Xu Jiaxiang, Wang Xiaoyu, Liu Wenhui, Liu Xuanjun, Li Guangshuai
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Public Health. 2025 Apr 30;13:1487177. doi: 10.3389/fpubh.2025.1487177. eCollection 2025.
This study aims to comprehensively analyze temporal trends in the burden of malignant melanoma (MM) in East Asia, focusing on incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1991 to 2021. It further seeks to compare these trends with the global burden of disease.
The study utilized data from the Global Burden of Disease (GBD) database to examine the disease burden of MM across East Asian countries and regions, as well as globally, over a 30-year period (1991-2021).
We assessed changes in the incidence, prevalence, mortality, and DALYs associated with MM in East Asia and globally using GBD database open-source data. To capture the underlying trends in the disease burden, we applied the Joinpoint regression model to calculate the average annual percentage change (AAPC) and corresponding 95% confidence intervals (95% CI). A detailed comparative analysis was conducted to explore differences in the burden of MM across East Asian regions and compared with global trends, with particular emphasis on age, sex, and temporal changes.
The greatest increase in MM incidence in East Asia was observed in Korea, where the age-standardized incidence rate (ASIR) rose from 0.603 cases per 100,000 population (95% CI: 0.389-0.789) in 1991 to 1.896 cases per 100,000 (95% CI: 0.78-2.499) in 2021. Regarding prevalence, China exhibited the most significant increase in East Asia, with the age-standardized prevalence rate (ASPR) increasing from 0.699 (95% CI: 0.451-0.864) per 100,000 in 1991 to 4.157 (95% CI: 2.195-5.633) per 100,000 in 2021. The highest increases in MM mortality and DALYs were noted in Taiwan Province of China, where the age-standardized mortality rate (ASMR) increased from 0.36 (95% CI: 0.339-0.382) per 100,000 in 1991 to 0.414 (95% CI: 0.414) per 100,000 in 2021. Similarly, the age-standardized DALY rate (ASDR) in Taiwan rose from 10.375 (95% CI: 9.781-11.049) per 100,000 in 1991 to 11.647 (95% CI: 10.558-12.478) per 100,000 in 2021. Age and gender exhibited distinct patterns of influence on the MM burden: while ASIR generally increased with age, ASPR initially increased and later plateaued. Both ASMR and ASDR demonstrated a positive correlation with age. Additionally, male populations consistently exhibited higher morbidity and mortality rates than females.
Over the period from 1991 to 2021, there were significant variations in the incidence, prevalence, mortality, and DALY rates of MM across East Asian countries and regions, including China, Japan, South Korea, North Korea, and Taiwan. These disparities underscore the need for region-specific, proactive prevention strategies and targeted public health interventions to mitigate the growing burden of malignant melanoma in the region.
本研究旨在全面分析东亚地区恶性黑色素瘤(MM)负担的时间趋势,重点关注1991年至2021年的发病率、患病率、死亡率和伤残调整生命年(DALYs)。本研究还试图将这些趋势与全球疾病负担进行比较。
本研究利用全球疾病负担(GBD)数据库的数据,考察了30年期间(1991 - 2021年)东亚国家和地区以及全球范围内MM的疾病负担。
我们使用GBD数据库的开源数据评估了东亚和全球范围内与MM相关的发病率、患病率、死亡率和DALYs的变化。为了捕捉疾病负担的潜在趋势,我们应用Joinpoint回归模型计算平均年度百分比变化(AAPC)和相应的95%置信区间(95%CI)。进行了详细的比较分析,以探讨东亚各地区MM负担的差异,并与全球趋势进行比较,特别强调年龄、性别和时间变化。
东亚地区MM发病率增长最大的是韩国,其年龄标准化发病率(ASIR)从1991年的每10万人口0.603例(95%CI:0.389 - 0.789)上升至2021年的每10万人口1.896例(95%CI:0.78 - 2.499)。在患病率方面,中国在东亚地区增长最为显著,年龄标准化患病率(ASPR)从1991年的每10万人口0.699例(95%CI:0.451 - 0.864)增至2021年的每10万人口4.157例(95%CI:2.195 - 5.633)。MM死亡率和DALYs增长最高的是中国台湾地区,其年龄标准化死亡率(ASMR)从1991年的每10万人口0.36例(95%CI:0.339 - 0.382)升至2021年的每10万人口0.414例(95%CI:0.414)。同样,台湾地区的年龄标准化DALY率(ASDR)从1991年的每10万人口10.375例(95%CI:9.781 - 11.049)升至2021年的每10万人口11.647例(95%CI:10.558 - 12.478)。年龄和性别对MM负担呈现出不同的影响模式:虽然ASIR总体上随年龄增加,但ASPR最初上升,随后趋于平稳。ASMR和ASDR均与年龄呈正相关。此外,男性人群的发病率和死亡率始终高于女性。
在1991年至2021年期间,包括中国、日本、韩国、朝鲜和台湾地区在内的东亚国家和地区,MM的发病率、患病率、死亡率和DALY率存在显著差异。这些差异凸显了制定针对特定区域的积极预防策略和有针对性的公共卫生干预措施的必要性,以减轻该地区恶性黑色素瘤日益加重的负担。